The last few months have marked the publication of research emerging from projects designed to collect and analyse genomic data on a wider scale than was previously thought possible. Scientists are not just studying specific mutations associated with medical conditions, but also establishing frameworks to understand the role of chromosomal instability and copy number changes in driving those disorders.

This month, we take a look at emerging research in this area, including that from the United Kingdom’s 100,000 Genomes Project, and understand how clinical applications could follow in the near future.

Also in this issue, a feature takes a look at how clinical trials measure pain, the challenges of developing drugs for neglected tropical diseases, and whether Russia’s domestic pharma capabilities may shield the country from the negative effects of the sanctions imposed on it following the war in Ukraine.

Don’t miss the data-led features on hiring trends for Internet-of-Things and digitalization-related jobs in the pharma industry.

Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.